Poster
Humanized TFRC and CD98hc mouse models for BBB and AAV brain delivery
An integrated BBB shuttle development workflow combining humanized TFRC and CD98hc mouse models with the HUGO-Nano™ fully human VHH discovery platform, demonstrating receptor-dependent antibody brain delivery in vivo and identifying anti-hTfR1 and anti-CD98hc nanobody candidates for CNS delivery of antibodies and AAV.

Overview
Delivering biologics to the CNS remains limited by the blood–brain barrier, with receptor-mediated transcytosis via TfR1 (TFRC) and CD98hc the leading strategy. We generated huTFRC, hTFRC(CDS), and huCD98HC(SLC3A2) mice, confirming human target expression at mRNA and protein level with colocalization to mCD31+ brain microvascular endothelium. Functionally, a TfR bispecific antibody showed significantly higher cerebral cortex accumulation and reduced plasma exposure at 24 h, while a CD98hc Shuttle achieved faster plasma clearance and significantly greater brain and parenchymal exposure peaking at Day 7. The HUGO-Nano™ platform yielded fully human VHHs binding native receptors at non-blocking epitopes with efficient endothelial internalization.
Key Insights
Validated humanized TFRC and CD98hc mouse models, paired with a fully human VHH discovery platform, form an integrated engine for developing and testing BBB shuttles for antibody and AAV brain delivery.
- Faithfully humanized BBB receptor models. huTFRC, hTFRC(CDS), and huCD98HC(SLC3A2) mice express the human target in place of the mouse ortholog across brain and peripheral tissues, with confirmed colocalization to the mCD31+ brain microvascular endothelium.
- Functional, receptor-dependent brain delivery demonstrated. A TfR bispecific antibody conjugate accumulated significantly more in the cerebral cortex than unconjugated protein at 24 h with reduced plasma levels, and a CD98hc Shuttle showed higher brain and parenchymal exposure than control IgG, peaking at Day 7.
- Fully human nanobody shuttles from HUGO-Nano™. The repertoire showed 97.8% full-length and 96.0% CDR3 sequence uniqueness, yielding anti-hTfR1 VHHs with benchmark-equivalent binding at a non-blocking, non-transferrin-competing epitope and anti-CD98hc VHHs with low-nanomolar affinity and efficient hCMEC/D3 internalization.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
